Find recruiting clinical trials for ovarian cancer in the UK � from first-line chemotherapy to PARP inhibitors and immunotherapy. See where trials fit into your treatment pathway.
Free to use � Live data from ClinicalTrials.gov � Updated daily
Answer a few questions about your condition and we'll match you to the most relevant clinical trials.
See where clinical trials fit into your treatment journey
Primary treatment involves debulking surgery followed by platinum-based chemotherapy
Standard: Carboplatin + paclitaxel (6 cycles) after optimal cytoreductive surgery
After chemotherapy response, PARP inhibitors maintain remission � especially for BRCA-mutated tumours
Standard: Olaparib, niraparib, or rucaparib as maintenance therapy (2�3 years)
Added to chemotherapy and continued as maintenance for high-risk disease
Standard: Bevacizumab alongside carboplatin/paclitaxel, then continued as single agent
For platinum-resistant relapse, trials explore immune checkpoint inhibitors and antibody-drug conjugates
Emerging: Pembrolizumab, dostarlimab, mirvetuximab soravtansine (FRa-targeted ADC)
Ovarian cancer is the 6th most common cancer in UK women, with about 7,500 new cases per year. It often presents at a late stage because early symptoms (bloating, abdominal pain, feeling full quickly) are vague. High-grade serous carcinoma is the most common subtype.
Despite advances in PARP inhibitors, most ovarian cancer patients still relapse. Only about 35% survive 10+ years. Trials are testing new combinations, ADCs, bispecific antibodies, and personalised vaccine approaches that could significantly improve outcomes.
About 15-20% of ovarian cancers are linked to BRCA1/2 gene mutations. All ovarian cancer patients in the NHS should be offered genetic testing. BRCA-mutated tumours respond especially well to PARP inhibitors, making them prime candidates for targeted therapy trials.
Loading trials from ClinicalTrials.gov...
Active research includes PARP inhibitors (Olaparib, Niraparib) in new combinations, antibody-drug conjugates, immunotherapy combinations, and novel targeted agents for specific molecular subtypes.
No. While PARP inhibitors were first approved for BRCA carriers, they are now used more broadly for HRD-positive (homologous recombination deficient) tumours. About 50% of ovarian cancers have HRD.
Yes. Many trials specifically target recurrent ovarian cancer, testing new drugs, drug combinations, and treatment sequences. Platinum-sensitive and platinum-resistant recurrence have different trial options.
Use our search above to find trials that match your condition and location. Review the eligibility criteria carefully.
Talk to your GP or specialist about any trials you are interested in. They can help determine if a trial is appropriate for you.
Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing. They will guide you through screening.
If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.